Elia Stupka, PhD

Senior Vice President and General Manager, Life Sciences, Health Catalyst

Dr. Elia Stupka is the Senior Vice President and General Manager of the Life Sciences business unit at Health Catalyst and contributes to the overall vision and growth for the company. He is a visionary leader in digital health with a passion for innovation in health and life sciences and 20 years of experience across industry, academic and clinical settings. In his role leading data science at Dana-Farber Cancer Institute, one of the world’s leading cancer organizations, Dr. Stupka brought together research, clinical and operational data to improve patient outcomes and the discovery of new treatments. He started his career as a member of the first team that annotated the human genome in Cambridge, U.K., in 1999-2001. He then worked with Nobel Laureate Sydney Brenner to build the first genome research group in Singapore. Subsequently, Stupka worked at several key European research organizations such as the Telethon Institute of Genetics in Naples, Italy and University College London. He then co-directed a genomics research center at San Raffaele Hospital in Milan, Italy, where he contributed to the successful development and completion of the first commercially viable gene therapy clinical trials in Europe. He worked several years in the pharma industry, at Boehringer Ingelheim Pharma, where he headed computational biology and genomics. He has published 100+ peer reviewed articles, cited 35,000+ times across the fields of drug development, data science and ethics. His work has contributed to the understanding of the human genome and transcriptome, the diagnosis of rare disease patients, the development of gene therapy and novel drugs on the market and the development of ethics frameworks pertaining to the fast-changing world of big data in health and biology.

Speaker Sessions

15 – How Real-World Data Can Rescue Clinical Trials and Save Lives (Panel) (Clinical, Life Sciences; Course Level-Beginning)

Every year clinical trials of vital therapies are canceled, not because the therapy isn’t promising but because of issues with trial feasibility or cost. This hurts all stakeholders: patients, healthcare providers, and pharmaceutical companies. Making trials more cost-effective and feasible means improving the way participants are identified and enrolled while also cutting the time and labor of collecting data. Many researchers say real-world evidence in the form of multiple-source enterprise data warehouse (EDW) data is the answer, but this requires bridging some gaps in interoperability and security. Learn from panel experts who work in all facets of clinical trials in this discussion about the promises and challenges of integrating EDW data into clinical trials.